Through the regulation of the miR‐526b‐3p/XBP1 signalling pathway, LINC02202 may play a role in tumour progression and immune infiltration and inhibiting the expression of LINC02202 can increase the efficacy of immunotherapy for melanoma. This evidence concerns the gene XBP1 and neoplasm.